Table 3. Risk Factors, BWH and AJCC 8 Tumor Stage, and Outcomes in Nodal Metastasis Cases.
| Location | Age, y/Sex | Immunosuppression | Previous Skin Cancer | Tumor Diameter, cm | Tumor Differentiation | Level of Invasion | Perineural Invasion | BWH T Stage | AJCC 8 T Stage | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| Vermilion | 50/M | No | No | Unknown | Well | Dermis | No | T1 | T1 | NM |
| Vermilion | 43/M | No | No | 0.4 | Well | Dermis | No | T1 | T1 | LR, NM, DSD, ACD |
| Vermilion | 66/F | No | Yes | 0.8 | Well | Dermis | No | T1 | T1 | LR, NM, DSD, ACD |
| Vermilion | 71/M | No | No | 1.3 | Well | Dermis | No | T1 | T1 | NM, DSD, ACD |
| Vermilion | 76/M | No | No | 1.5 | Well | Dermis | No | T1 | T1 | NM |
| Vermilion | 75/M | Yes | Yes | 1.8 | Well | Dermis | No | T1 | T1 | NM, DSD, ACD |
| Vermilion | 84/M | Yes | Yes | 2.4 | Well | Dermis | No | T2a | T2 | LR, NM, ACD |
| Vermilion | 72/M | No | Yes | 0.5 | Moderate | Dermis | No | T1 | T1 | LR, NM, ACD |
| Vermilion | 74/F | No | Yes | 0.8 | Moderate | Dermis | No | T1 | T1 | NM |
| Vermilion | 59/M | No | No | 1.8 | Moderate | Muscle | No | T2a | T3 | NM |
| Vermilion | 74/F | No | Yes | 1.8 | Moderate | Muscle | No | T2a | T3 | NM |
| Vermilion | 71/F | No | No | 1.1 | Poor | Dermis | No | T2a | T1 | NM |
| Vermilion | 61/F | No | No | 2.5 | Poor | Dermis | Yes | T2b | T2 | NM |
| Cutaneous | 62/M | No | No | 1.1 | Well | Muscle | No | T2a | T3 | NM, DSD, ACD |
| Cutaneous | 81/F | No | Yes | 1.4 | Moderate | Muscle | No | T2a | T3 | LR, NM, DSD, ACD |
Abbreviations: ACD, all-cause death; AJCC 8, American Joint Committee on Cancer Cancer Staging Manual, 8th Edition; BWH, Brigham and Women’s Hospital staging system; DSD, disease-specific death; LR, local recurrence; NM, nodal metastasis.